¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"venom substrate"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • snake venom
    ¹ìµ¶
  • venom
    µ¶
  • venom gland
    µ¶»ù, µ¶¼±
  • venom hemolysis
    ¹ìµ¶¿ëÇ÷
  • insulin receptor substrate-1
    Àν¶¸°¼ö¿ëü±âÁú-1
  • renin substrate
    ·¹´Ñ±âÁú
  • respiratory substrate
    È£Èí±âÁú
  • substrate
    ±âÁú
  • substrate mycelium
    ±âÁú±Õ»çü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • venom
    µ¶¹°, ¹ìµ¶
  • substrate
    ±âÁú
  • renin substrate
    ·¹´Ñ±âÁú
  • respiratory substrate
    È£Èí±âÁú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • venom duct
    µ¶°ü
  • venom gland
    µ¶»ù
  • venom hemolysis
    ¹ìµ¶¿ëÇ÷
  • substrate-labeled fluorescence immunoassay
    ±âÁúÇ¥ÁöÇü±¤¸é¿ªºÐ¼®(¹ý)
  • substrate mycelium
    ±âÁú±Õ»çü
  • renin substrate
    ·¹´Ñ±âÁú
  • respiratory substrate
    È£Èí±âÁú
  • substrate
    ±âÁú
  • snake venom
    ¹ìµ¶
  • venom
    µ¶¹°, ¹ìµ¶
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Russells viper venom time
    ·¯¼¿¹ÙÀÌÆÛº£³ð½Ã°£
  • SLFIA => substrate-labeled fluorescence imunoassay
    ±âÁúÇ¥ÁöÇü±¤¸é¿ªÃøÁ¤(¹ý)
  • hippurate substrate
    ¸¶´¢»ê±âÁú
  • renin substrate
    ·¹´Ñ±âÁú.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hippurate substrate
    ¸¶´¢»ê±âÁú
  • leading substrate
    ¼±µµ±âÁú.
  • mycelium, substrate
    ±âÁú±Õ»çü
  • renin substrate
    ·¹´Ñ±âÁú.
  • respiratory substrate
    È£Èí±âÁú(û¼ýåѨòõ), È£Èí¹°Áú(û¼ýåÚªòõ).
  • substrate
    ±âÁú
  • substrate level phosphorylation
    ±âÁú±Þ ÀλêÈ­.
  • substrate-labeled fluorescence immunoassay(sLFIA)
    ±âÁúÇ¥ÁöÇü±¤¸é¿ªÃøÁ¤(¹ý)
  • cobra venom
    ÄÚºê¶óµ¶.
  • snake venom
    ¹ìµ¶(¡­Ô¸).
  • snake venom
    ¹ìµ¶(¡­Ô¸)
  • venom duct
    µ¶°ü(Ըη).
  • venom fang
    µ¶¾Æ(Ô¸ä´).
  • venom hemolysis
    »çµ¶¿ëÇ÷(ÞïÔ¸éÁúì).
  • venom hemolysis
    »çµ¶¿ëÇ÷(ÞïÔ¸éÁúì).
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • venom gland
    µ¶»ù
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • venom substrate
    »çµ¶(ÞïÔ¸) ±âÁú(Ðñòõ)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • covalent enzyme-substrate complex
    È¿¼Ò±âÁú °øÀ¯°áÇÕü(ý£áÈÐñòõÍìêóÌ¿ùêô÷) (ÔÒ) enzymesubstrate compound
  • enzyme-substrate complex
    È¿¼Ò-±âÁú º¹ÇÕü (ý£áÈÐñòõÜÜùêô÷)
  • enzyme-substrate compound
    È¿¼Ò-±âÁú È­ÇÕ¹° (ý£áÈÐñòõûùùêÚª)
  • enzyme-substrate intermediate
    È¿¼Ò-±âÁú Áß°£Ã¼ (ý£áÈÐñòõñéÊàô÷)
  • inverse substrate
    ¿ª ±âÁú(æ½Ðñòõ)
  • leading substrate
    ¼±µµ±âÁú(à»ÓôѨòõ)
  • normalized substrate concentration
    ³ë¸£¸» ±âÁú³óµµ(ѨòõÒØÓø)
  • reduced substrate concentration
    ȯ»ê ±âÁú ³óµµ(üµß©Ñ¨òõÒØÓø)
  • relative substrate concentration
    »ó´ë ±âÁú³óµµ(ßÓÓßÐñòõÒØÓø)
  • renin substrate
    ·¹´Ñ ±âÁú(Ðñòõ)
  • saturating substrate concentration
    Æ÷È­ ±âÁú³óµµ(øéûùÐñòõÒØÓø)
  • single-substrate enzyme
    ´Ü±âÁúÈ¿¼Ò(Ó¤Ðñòõý£áÈ)
  • solid substrate room temperature phosphorescence
    °íü±âÁú ½Ç¿ÂÀα¤¹ý(ͳô÷Ðñòõ ãøè®ìÝÎÃÛö)
  • specific substrate concentration
    ƯÀÌ ±âÁú³óµµ(÷åì¶ÐñòõÒØÓø)
  • stationary substrate
    Á¤Áö ±âÁú (ïÎò­Ðñòõ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • venom
    µ¶¾×, µ¶¹°
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ASV anodic stripping voltammetry; antisiphon valve; antisnake venom; avian sarcoma virus
BWSV black widow spider venom
CoVF cobra venom factor
CVF cardiovascular failure; central visual field; cervicovaginal fluid; cobra venom factor
dRVVT dilute Russell viper venom time
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
BV Bee venom
BWSV Black Widow Spider Venom
CVF Cobra Venom Factor
CoF Cobra venom factor
CoVF Cobra venom factor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • bee venom
    ¹úµ¶
    ¹ú ¾Ë·¹¸£±â¸¦ ÀÏÀ¸Å°´Â ÁÖ¿ä ¾Ë·¹¸£±â¿ø. ¹ú ¾Ë·¹¸£±â¶õ ¹ú¿¡ ½î¿´À» ¶§ ¹ßÁõÇÏ´Â ±× µ¶¿¡ ´ëÇÑ Áï½ÃÇü °ú¹ÎÁõÀ» ¸»ÇÑ´Ù. Áõ»óÀº ¾Æ³ªÇʶô½Ã½º¿Í °°ÀÌ ½ÉÇÑ °ÍÀ̳ª µÎµå·¯±â¿Í °°ÀÌ ºñ±³Àû °æÇÑ °ÍµéÀÌ Æ÷ÇԵȴÙ. ¹ú µ¶¿¡ Æ÷ÇԵǾî ÀÖ´Â ÁÖ¿ä Ç׿ø ¹°Áú·Î¼­´Â mellitin,
  • leading substrate
    ¼±µµ ±âÁú
  • neuroanatomic substrate
    ½Å°æ ÇØºÎÇÐÀû ±âÁú, ½Å°æ ÇØºÎÇÐÀû ¹°Áú
  • substrate level phosphorylation
    ±âÁú±Þ ÀλêÈ­
  • zymolite µ¿ÀǾî=substrate.

    zymologist

    È¿¼ÒÇÐÀÚ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
substrate <chemistry> A substance upon which an enzyme acts.
Origin: L. Stratum = layer
(18 Nov 1997)
substrate cycle <biochemistry> Any seqence of enzyme catalysed reactions in which the forward and reverse processes (catalysed by different enzymes) are consititutively active.
Frequently used to describe the cycle of phosphorylation and dephosphorylation of phosphatidyl inositol derivatives in cell membranes.
(05 Jan 1998)
substrate cycling A set of opposing, nonequilibrium reactions catalyzed by different enzymes which act simultaneously, with at least one of the reactions driven by ATP hydrolysis. The results of the cycle are that ATP energy is depleted, heat is produced and no net substrate-to-product conversion is achieved. Examples of substrate cycling are cycling of gluconeogenesis and glycolysis pathways and cycling of the triglycerides and fatty acid pathways. Rates of substrate cycling may be increased many-fold in association with hypermetabolic states resulting from severe burns, cold exposure, hyperthyroidism, or acute exercise.
(12 Dec 1998)
substrate inhibition Inhibition of an enzyme activity by a substrate of the reaction catalyzed by that enzyme; often, this type of inhibition occurs at elevated substrate levels in which the substrate is binding to a second, non-active site on the enzyme.
(05 Mar 2000)
substrate-level phosphorylation Synthesis of high-energy phosphate bonds through reaction of inorganic phosphate with an activated (usually) organic substrate.
(09 Oct 1997)
substrate specificity A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts.
(12 Dec 1998)
suicide substrate A competitive inhibitor that is converted to an irreversible inhibitor at the active site of the enzyme.
Synonym: mechanism-based inhibitor.
(05 Mar 2000)
insulin receptor substrate-1 protein <chemical> Amino acid sequence given in first source; a 180 kD protein that contains multiple phosphorylated tyrosine residues after insulin stimulation; human and rat forms (hirs-1 and irs-1) are homologous
Synonym: insulin receptor substrate-1-like protein, irs-1 protein, irs-1 gene product, hirs-1 protein, hirs-1 gene product, insulin receptor substrate 1, insulin receptor substrate-1
(05 Dec 1998)
enzyme-substrate complex A noncovalent complex of two molecules; often referring to the enzyme-substrate complex in an enzyme-catalyzed reaction.
Compare: central complex, Michaelis complex.
Synonym: enzyme-substrate complex.
(05 Mar 2000)
black widow spider venom Potent neurotoxin that induces catastrophic release of acetylcholine from presynaptic terminals of cholinergic chemical synapses.
(18 Nov 1997)
venom <chemical> A toxic secretion in animals that is actively delivered to the target organism, either to paralyse or incapacitate or else to cause pain as a defence mechanism. Commonly include protein and peptide toxins.
(12 Jan 1998)
venom haemolysis That caused by haemolytic material in the venom of various species of snakes or other venomous animals.
(05 Mar 2000)
Russell's viper venom A venom used as a coagulant in the arrest of haemorrhage from accessible sites in haemophilia.
(05 Mar 2000)
Russell's viper venom clotting time A clotting time determination performed on citrated platelet-poor plasma using Russell's viper venom as an activating agent. This allows activation of factor X directly without the need for other coagulation factors and is used to confirm factor X defects.
See: Stypven time test.
(05 Mar 2000)
cobra venom cofactor <enzyme> A glycine-rich, heat-labile beta-glycoprotein found in blood. It is a proactivator of complement 3 in the alternate pathway of complement activation. Factor b is converted by factor d to c3 convertase.
Registry number: EC 3.4.21.47
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • substrate
    ±âÁú(È¿¼ÒÀÇ ÀÛ¿ëÀ¸·Î È­ÇйÝÀÀÀ» ÀÏÀ¸Å°´Â ¹°Áú);(¼¼±ÕÀÇ)¹è¾ç±â
  • venom
    µ¶
  • venom
    (¹ì,°Å¹Ì µûÀ§ÀÇ)µ¶;¾ÇÀÇ;¿øÇÑ;µ¶¼³
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á